drugset / Trial / NCT06721091
Safety, Tolerability, and Dose Response of VNA-318 in Healthy Males
RandomizedSequentialQuadruple-blindOther
Summary
This is a phase 1, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses (SAD) and multiple ascending doses (MAD) of VNA-318 in healthy male subjects.
Timeline
- Start
- 2024-12-03
- Primary completion
- 2025-11-27
- Completion
- 2025-11-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VNA-318 | Unknown | 5 mg | Oral |
| Subject | VNA-318 | Unknown | 180 mg | Oral |
Indications
No indication recorded.